Pragati Agnihotri

Pragati Agnihotri

Auto-generated profile, based on publicly available information

Pragati Agnihotri

Molecular and Structural Biology Division, CSIR-Central Drug Research Institute, B.S. 10/1, Sector 10, Jankipuram Extension, Sitapur Road, Lucknow, 226031, U.P., India

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2019 in Journal of Biological Chemistry
Verified
Journal Article
Closed access
PDF file
RMRoy A. Mariuzza
Roy A. Mariuzza
PAPragati Agnihotri
Pragati Agnihotri
JOJohn Orban
John Orban

2 April 2014 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Rahul ShivahareRahul Shivahare
Rahul Shivahare
VKVenkateswarlu Korthikunta
Venkateswarlu Korthikunta
HCHardik Chandasana
Hardik Chandasana
MSManish K. Suthar
Manish K. Suthar
PAPragati Agnihotri
Pragati Agnihotri
NTNarender Tadigoppula
Narender Tadigoppula

8 April 2020 in ACS Applied Bio Materials
Verified
Journal Article
Closed access
Alexander AndrianovAlexander Andrianov
Alexander Andrianov
AMAlexander Marin
Alexander Marin
RWRuixue Wang
Ruixue Wang
HKHatice Karauzum
Hatice Karauzum
ACAnanda Chowdhury
Ananda Chowdhury
TFThomas Fuerst
Thomas Fuerst

27 October 2020 in Journal of Virology
Verified
Journal Article
Closed access
BPBrian G. Pierce
Brian G. Pierce
ZKZhen-Yong Keck
Zhen-Yong Keck
RWRuixue Wang
Ruixue Wang
PLPatrick Lau
Patrick Lau
KGKyle Garagusi
Kyle Garagusi
SFSteven Foung
Steven Foung
Hepatitis C virus infects approximately 1% of the world’s population, and no vaccine is currently available. Due to the high variability of HCV and its ability to actively escape the immune response, a goal of HCV vaccine design is to induce neutralizing antibodies that target conserved epitopes. Here, we performed structure-based design of several epitopes of the HCV E2 envelope glycoprotein to engineer its antigenic properties. Designs were tested in vitro and in vivo , demonstrating alteration of the E2 antigenic profile in several cases, and one design led to improvement of cross-neutralization of heterologous viruses. This represents a proof of concept that rational engineering of HCV envelope glycoproteins can be used to modulate E2 antigenicity and optimize a vaccine for this challenging viral target.

27 May 2017 in Journal of Computer-Aided Molecular Design
Verified
Journal Article
Closed access
PDF file
AMArjun K. Mishra
Arjun K. Mishra
NSNidhi Singh
Nidhi Singh
PAPragati Agnihotri
Pragati Agnihotri
SMShikha Mishra
Shikha Mishra
SSSaurabh P. Singh
Saurabh P. Singh
JPJ. Venkatesh Pratap
J. Venkatesh Pratap

23 June 2020 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
Alexander AndrianovAlexander Andrianov
Alexander Andrianov
AMAlexander Marin
Alexander Marin
RWRuixue Wang
Ruixue Wang
ACAnanda Chowdhury
Ananda Chowdhury
PAPragati Agnihotri
Pragati Agnihotri
TFThomas Fuerst
Thomas Fuerst